13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001056807
Total reported value
$3.9B
$3.9B
41 檔
34.0%
At the close of Q4 2025, Bvf Inc/il disclosed equity holdings valued at approximately $3.9B, spread across 41 reported holdings.
In Q4 2025, Bvf Inc/il adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 7 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including KYMR, RVMD, MLTX) accounted for 34.0% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc | Stock-Other | 14.41% | -3.25% | — | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 9.00% | +5.35% | -15.55% | |
| 3 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 8.76% | -1.53% | — | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 8.15% | -0.69% | +8.59% | |
| 5 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 4.46% | -0.83% | — | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 3.98% | -1.50% | — | |
| 7 | GHRS | GH Research PLC | Stock-Other | 3.77% | +2.08% | — | |
| 8 | XNCR | Xencor Inc | Stock-Other | 3.68% | +0.20% | +160.34% | |
| 9 | ZYME | Zymeworks Inc | Stock-Other | 3.49% | -0.54% | — | |
| 10 | PVLA | Palvella Therapeutics Inc | Stock-Other | 3.10% | -1.19% | -24.30% | |
| 11 | KURA | Kura Oncology Inc | Stock-Other | 3.01% | +0.18% | — | |
| 12 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.42% | -0.51% | +36.73% | |
| 13 | XOMA | Xoma Royalty Corporation | Stock-Other | 2.32% | +5.66% | — | |
| 14 | ABVX | Abivax Sa-adr | Stock-Other | 2.31% | — | -8.96% | |
| 15 | NKTR | Nektar Therapeutics | Stock-Other | 2.22% | -1.60% | +22.17% | |
| 16 | ACIU | AC Immune SA | Stock-Other | 2.10% | -0.53% | — | |
| 17 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.02% | +0.42% | -32.23% | |
| 18 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 2.00% | +0.08% | — | |
| 19 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.88% | -1.20% | -41.70% | |
| 20 | IRON | Disc Medicine Inc | Stock-Other | 1.74% | -0.43% | — | |
| 21 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.69% | -0.19% | -5.42% | |
| 22 | IVVD | Invivyd Inc | Stock-Other | 1.62% | -0.18% | — | |
| 23 | SEPN | Septerna Inc | Stock-Other | 1.61% | -1.04% | EXIT | |
| 24 | ANNX | Annexon Inc | Stock-Other | 1.54% | -0.27% | +30.40% | |
| 25 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.40% | -1.31% | EXIT | |
| 26 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.17% | +0.13% | — | |
| 27 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.10% | -0.34% | +98.06% | |
| 28 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.96% | -0.16% | — | |
| 29 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.90% | — | — | |
| 30 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.83% | +0.20% | +0.00% | |
| 31 | PEPG | Pepgen Inc | Stock-Other | 0.42% | — | — | |
| 32 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.32% | +0.01% | — | |
| 33 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 0.30% | -0.02% | — | |
| 34 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.28% | — | -90.60% | |
| 35 | MOLN | Molecular Partners AG -adr | Stock-Other | 0.20% | -0.04% | — | |
| 36 | IMA | Imagenebio Inc | Stock-Other | 0.19% | -0.01% | — | |
| 37 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.18% | -0.04% | — | |
| 38 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.14% | -0.04% | — | |
| 39 | VTLUSD | Immunic Inc | Stock-Other | 0.14% | -0.27% | EXIT | |
| 40 | IVA | Inventiva SA - Adr | Stock-Other | 0.11% | -0.05% | — | |
| 41 | ✓ | Engene Holdings Inc | Stock-Other | 0.08% | -0.08% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GPCR | Structure Therapeutics Inc | +4.5% | +8.59% | Add |
| 2 | MLTX | Moonlake Immunotherapeutics | +3% | — | Unchanged |
| 3 | XNCR | Xencor Inc | +2.4% | +160.34% | Add |
| 4 | OLMA | Olema Pharmaceuticals Inc | +2.4% | — | Unchanged |
| 5 | KYMR | Kymera Therapeutics Inc | +1.8% | — | Unchanged |
| 6 | RVMD | Revolution Medicines Inc | +1.5% | -15.55% | Trim |
| 7 | STOK | Stoke Therapeutics Inc | +0.8% | +36.73% | Add |
| 8 | ZYME | Zymeworks Inc | +0.8% | — | Unchanged |
| 9 | CMPX | Compass Therapeutics Inc | +0.7% | +63.47% | Add |
| 10 | ANNX | Annexon Inc | +0.7% | +30.40% | Add |
| 11 | CGEM | Cullinan Therapeutics Inc | +0.6% | — | Unchanged |
| 12 | ✓ | Crescent Biopharma Inc. | +0.4% | +98.06% | Add |
| 13 | ABVX | Abivax Sa-adr | +0.4% | -8.96% | Trim |
| 14 | GLUE | Monte Rosa Therapeutics Inc | +0.3% | -32.23% | Trim |
| 15 | RPTX | Repare Therapeutics Inc | +0.2% | — | Unchanged |
| 16 | PVLA | Palvella Therapeutics Inc | +0.2% | -24.30% | Trim |
| 17 | AVTX | Avalo Therapeutics Inc | +0.1% | +0.00% | Add |
| 18 | PEPG | Pepgen Inc | +0.1% | — | Unchanged |
| 19 | ✓ | Engene Holdings Inc | +0.1% | — | Unchanged |
| 20 | TENX | Tenax Therapeutics Inc | 0% | — | Unchanged |
| 21 | MOLN | Molecular Partners AG -adr | — | — | Unchanged |
| 22 | XFOR | X4 Pharmaceuticals Inc | 0% | — | Unchanged |
| 23 | IVA | Inventiva SA - Adr | -0.1% | — | Unchanged |
| 24 | IMA | Imagenebio Inc | -0.1% | — | Unchanged |
| 25 | KURA | Kura Oncology Inc | -0.1% | — | Unchanged |
| 26 | FHTX | Foghorn Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | VTLUSD | Immunic Inc | -0.1% | — | Unchanged |
| 28 | TYRA | Tyra Biosciences Inc | -0.2% | -41.70% | Trim |
| 29 | TCRX | Tscan Therapeutics Inc | -0.2% | — | Unchanged |
| 30 | ACIU | AC Immune SA | -0.2% | — | Unchanged |
| 31 | ELDN | Eledon Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 32 | MIRM | Mirum Pharmaceuticals Inc | -0.5% | — | Unchanged |
| 33 | FDMT | 4d Molecular Therapeutics In | -0.5% | — | Unchanged |
| 34 | IMCR | Immunocore Holdings Plc-adr | -0.6% | -5.42% | Trim |
| 35 | NKTR | Nektar Therapeutics | -0.7% | +22.17% | Add |
| 36 | GHRS | GH Research PLC | -1.4% | — | Unchanged |
| 37 | SEPN | Septerna Inc | -1.5% | -57.15% | Trim |
| 38 | XOMA | Xoma Royalty Corporation | -1.7% | — | Unchanged |
| 39 | AXSM | Axsome Therapeutics Inc | -2.1% | -90.60% | Trim |
| 40 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 41 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 42 | IRON | Disc Medicine Inc | — | NEW | New buy |
| 43 | IVVD | Invivyd Inc | — | NEW | New buy |
| 44 | CELC | Celcuity Inc | — | EXIT | Sold out |
| 45 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 46 | SABS | Sab Biotherapeutics Inc | — | EXIT | Sold out |
| 47 | FBRX | Forte Biosciences Inc | — | EXIT | Sold out |
| 48 | ✓ | Nls Pharmaceutics LTD | — | EXIT | Sold out |
According to official SEC Form 13F filings, Bvf Inc/il reported a total U.S. public equity portfolio value of $3.9B across 41 disclosed positions in Q4 2025.
During Q4 2025, Bvf Inc/il's top holdings by market value included KYMR (14.4%)、RVMD (9.0%)、MLTX (8.8%). The largest single position, KYMR, represented 14.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
IRON
市值: $51.6M
Top Position Liquidated / Trimmed
PTGX
前期市值: $170.1M
In Q4 2025, Bvf Inc/il made 25 total portfolio adjustments, initiating 2 new buys, adding to 8 positions, trimming 8 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.